Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy
Cardiovascular Drugs and Therapy · 2025
DOI: 10.1007/s10557-024-07652-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cardiovascular Drugs and Therapy, 2025. Verfasst von Dorsa Alijanzadeh und 5 weiteren Autor:innen. Beteiligte Einrichtung: Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran. Hauptthemen laut MEDLINE: Atrial Fibrillation, Benzazepines, Anti-Arrhythmia Agents, Cardiovascular Agents. Die Arbeit nennt 91 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Student Research Committee, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Faculty of Pharmacy, Mazandaran University of Medical Sciences, Sari, Iran.
- School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
- Cardiovascular Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran. isa_khaheshi@yahoo.com.
ORCID-Profile: Isa Khaheshi
Zitieren
APA
Alijanzadeh, D., Moghim, S., Zarand, P., Akbarzadeh, M. A., Zarinfar, Y., & Khaheshi, I. (2025). Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy. Cardiovascular Drugs and Therapy. https://doi.org/10.1007/s10557-024-07652-3
Vancouver
Alijanzadeh D, Moghim S, Zarand P, Akbarzadeh MA, Zarinfar Y, Khaheshi I. Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy. Cardiovascular Drugs and Therapy. 2025. doi:10.1007/s10557-024-07652-3
BibTeX
@article{Alijanzadeh2025,
author = {Alijanzadeh, Dorsa and Moghim, Shahrzad and Zarand, Paniz and Akbarzadeh, Mohammad Ali and Zarinfar, Yasaman and Khaheshi, Isa},
title = {Reassessing Ivabradine: Potential Benefits and Risks in Atrial Fibrillation Therapy},
journal = {Cardiovascular Drugs and Therapy},
year = {2025},
doi = {10.1007/s10557-024-07652-3}
}
EUVIMED